Early Treatment for CML: A Closer Watch and Newer Options for Better Long-Term Results
Dr. Jorge Cortes, deputy chair of the leukemia department at MD Anderson Cancer Center, explains the maturing treatment and monitoring options for newly diagnosed patients with CML. He explains how physicians are taking a critical look at the first three months of treatment and placing an emphasis on early response. He also discusses the use of second-generation TKIs in frontline therapy and newer agents becoming available to treat patients who develop mutations.
Experts & Guests
Jorge Cortes, M.D.
Chair of the CML Section in the Department of Leukemia , MD Anderson Cancer CenterDr. Jorge Eduardo Cortes is Chair of the CML Section in the Department of Leukemia at The University of Texas MD Anderson Cancer Center and is also D. B. Lane Cancer Research Distinguished Professor for Leukemia Research. Dr. Cortes attended medical school at Universidad Nacional Autónoma de Mexico in Mexico City, Mexico. He went on to complete fellowships in hematology... more >